Bessemer Group Inc. Sells 1,903 Shares of Inari Medical, Inc. (NASDAQ:NARI)

Bessemer Group Inc. cut its stake in shares of Inari Medical, Inc. (NASDAQ:NARI) by 72.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 737 shares of the company’s stock after selling 1,903 shares during the quarter. Bessemer Group Inc.’s holdings in Inari Medical were worth $37,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of NARI. Norges Bank bought a new position in Inari Medical in the fourth quarter worth approximately $14,447,000. Jennison Associates LLC grew its position in shares of Inari Medical by 11.8% during the 4th quarter. Jennison Associates LLC now owns 1,763,258 shares of the company’s stock worth $90,014,000 after buying an additional 186,617 shares in the last quarter. Evoke Wealth LLC grew its position in shares of Inari Medical by 207.5% during the 4th quarter. Evoke Wealth LLC now owns 192,926 shares of the company’s stock worth $9,849,000 after buying an additional 130,186 shares in the last quarter. American Century Companies Inc. increased its stake in shares of Inari Medical by 9.1% during the fourth quarter. American Century Companies Inc. now owns 1,068,487 shares of the company’s stock valued at $54,546,000 after buying an additional 89,108 shares during the period. Finally, Lisanti Capital Growth LLC bought a new stake in shares of Inari Medical in the fourth quarter valued at about $3,969,000. Institutional investors own 90.98% of the company’s stock.

Inari Medical Price Performance

Shares of Inari Medical stock opened at $79.97 on Friday. The company has a 50 day moving average price of $79.96 and a 200 day moving average price of $65.21. The firm has a market capitalization of $4.68 billion, a P/E ratio of -59.24 and a beta of 1.02. Inari Medical, Inc. has a 52 week low of $36.73 and a 52 week high of $79.99.

Wall Street Analysts Forecast Growth

NARI has been the topic of a number of research reports. William Blair reissued a “market perform” rating on shares of Inari Medical in a research report on Tuesday, January 7th. Baird R W lowered shares of Inari Medical from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 7th. Wells Fargo & Company restated an “equal weight” rating and set a $80.00 target price (up previously from $65.00) on shares of Inari Medical in a report on Tuesday, January 7th. Canaccord Genuity Group reiterated a “hold” rating and issued a $80.00 price target (up from $74.00) on shares of Inari Medical in a report on Tuesday, January 7th. Finally, Robert W. Baird restated a “neutral” rating and set a $80.00 price objective (down from $81.00) on shares of Inari Medical in a research note on Tuesday, January 7th. Twelve analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $68.00.

About Inari Medical

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.